Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study.

MLA

Cousin, Sophie, et al. “Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of Molibresib for the Treatment of Nuclear Protein of the Testis Carcinoma and Other Cancers: Results of a Phase I/II Open‐label, Dose Escalation Study.” International Journal of Cancer, vol. 150, no. 6, Mar. 2022, pp. 993–1006. EBSCOhost, https://doi.org/10.1002/ijc.33861.

APA

Cousin, S., Blay, J., Garcia, I. B., de Bono, J. S., Le Tourneau, C., Moreno, V., Trigo, J., Hann, C. L., Azad, A. A., Im, S., Cassier, P. A., French, C. A., Italiano, A., Keedy, V. L., Plummer, R., Sablin, M., Hemming, M. L., Ferron, B. G., Wyce, A., & Khaled, A. (2022). Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study. International Journal of Cancer, 150(6), 993–1006. https://doi.org/10.1002/ijc.33861

Chicago

Cousin, Sophie, Jean‐Yves Blay, Irene Braña Garcia, Johann S. de Bono, Christophe Le Tourneau, Victor Moreno, Jose Trigo, et al. 2022. “Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of Molibresib for the Treatment of Nuclear Protein of the Testis Carcinoma and Other Cancers: Results of a Phase I/II Open‐label, Dose Escalation Study.” International Journal of Cancer 150 (6): 993–1006. doi:10.1002/ijc.33861.